Merck Announces Initial Results for KEYTRUDA® (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress
Dateline City:
KENILWORTH, N.J.
In Addition, Longer Term Follow-Up Single-Agent Data for KEYTRUDA Shows Continued Superior Overall Response Rate and Progression Free Survival Compared to Ipilimumab
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced findings from three studies investigating the use of
KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy,
in combination with three other im...
Source: Merck.com - Product News - November 21, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News #Merck #MRK $MRK cancer Keytruda MSD NYSE:MRK Source Type: news
GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment
Dateline City:
LONDON & KENILWORTH, N.J.
Phase I first-in-human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)
LONDON & KENILWORTH, N.J.--(BUSINESS WIRE)--GSK and Merck, known as MSD outside the US and Canada, today announced
the initiation of a phase I clinical trial designed to evaluate GSK’s
investigational immunotherapy GSK3174998 as monotherapy and in
...
Source: Merck.com - Product News - November 3, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA ® (pembrolizumab) in Advanced Colorectal Cancer
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability < /p > < /div > < /div...
Source: Merck.com - Product News - November 2, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News #cancer #Merck #MRK $MRK colorectal cancer Keytruda MSD NYSE:MRK Source Type: news
Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Advanced Colorectal Cancer
Dateline City:
KENILWORTH, N.J.
Designation Based on Results in Patients with Metastatic Colorectal Cancer with High Levels of Microsatellite Instability
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
granted Breakthrough Therapy Designation to KEYTRUDA®
(pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of
patients wit...
Source: Merck.com - Product News - November 2, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck ’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016 < /p > < /div > < /div > < /div > < p > KENI...
Source: Merck.com - Product News - October 26, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
Dateline City:
KENILWORTH, N.J.
Merck Plans Regulatory Submissions in the U.S. in late 2015 and in the European Union in Early 2016
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced topline results from the KEYNOTE-010 study of KEYTRUDA®
(pembrolizumab) in advanced non-small-cell lung cancer (NSCLC)
demonstrating that the trial met its primary objective.
Language:
...
Source: Merck.com - Product News - October 26, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA® (pembrolizumab) for Advanced Gastric Cancer
Dateline City:
ROCKVILLE, Md. and KENILWORTH, N.J.
Clinical trial to evaluate MacroGenics' Fc-optimized anti-HER2 antibody with Merck's anti-PD-1 therapy in patients with advanced HER2-positive gastric cancer
ROCKVILLE, Md.and KENILWORTH, N.J.
Language:
English
read more (Source: Merck.com - Product News)
Source: Merck.com - Product News - October 22, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda® (pembrolizumab) as First-line Treatment for Advanced Melanoma
Dateline City:
WILMINGTON, Del. and KENILWORTH, N.J.
Pivotal study to evaluate Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with advanced or metastatic melanoma
WILMINGTON, Del. and KENILWORTH, N.J. -- Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies’ ongoing clinical collaboration to include a Phase 3 study evaluating the combination of epacadostat, Incyte’s ...
Source: Merck.com - Product News - October 13, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
FDA Approves KEYTRUDA ® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Patients with EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression on FDA-Approved Therapy for These Aberrations Prior t...
Source: Merck.com - Product News - October 2, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
FDA Approves KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
Dateline City:
KENILWORTH, N.J.
Patients with EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression on FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA® (pembrolizumab) monotherapy, the company’s
anti-PD-1 (programmed death receptor-1) ...
Source: Merck.com - Product News - October 2, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer
Dateline City:
KENILWORTH, N.J. & HOUSTON
KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
DNAtrix today announced they have entered into an oncology clinical
study collaboration to evaluate the efficacy and safety of DNX-2401,
DNAtrix’s oncolytic immunotherapy, in combination with KEYTRUDA®
(pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered
study of patients with recurrent glioblastoma, the most aggressive form
of brain cancer for...
Source: Merck.com - Product News - October 1, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
MARIZEV ® (Omarigliptin), Merck’s Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Japanese Pharmaceuticals and Medical Devices
Agency (PMDA) has approved MARIZEV < sup > ® < /sup > (omarigliptin) 25 mg ...
Source: Merck.com - Product News - September 28, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
MARIZEV® (Omarigliptin), Merck’s Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Japanese Pharmaceuticals and Medical Devices
Agency (PMDA) has approved MARIZEV® (omarigliptin) 25 mg and
12.5 mg tablets, an oral, once-weekly DPP-4 inhibitor indicated for the
treatment of adults with type 2 diabetes. Japan is the first country to
have approved omarigliptin.
Language:
English
Conta...
Source: Merck.com - Product News - September 28, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
New Data from KEYNOTE-028, Merck ’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Findings Show Anti-Tumor Activity for KEYTRUDA in Two Gastrointestinal Cancers < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a t...
Source: Merck.com - Product News - September 27, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
New Data from KEYNOTE-028, Merck’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress
Dateline City:
KENILWORTH, N.J.
Findings Show Anti-Tumor Activity for KEYTRUDA in Two Gastrointestinal Cancers
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced new findings from the KEYNOTE-028 Phase 1b study, the
clinical trial investigating the use of the company’s anti-PD-1 therapy,
KEYTRUDA® (pembrolizumab) in multiple, difficult-to-treat
cancers. Data from this trial, to be presented at...
Source: Merck.com - Product News - September 27, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
